PerPrev-CID Personalized disease prediction and prevention in chronic inflammatory disorders
- Coordinator
- Universitatsklinikum Schleswig-Holstein, Germany
- Runs
- 1 January 2025 to 31 December 2029
- Status
- Running
- EU funding
- €11.0m
- Total cost
- —
- Partners
- 15 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101156542
What the project is doing
In the project's own words, from its summary on CORDIS.
Background: Chronic inflammatory diseases (CID) are a group of non-communicable disorders of the immune system with a lifetime prevalence of over 10% in the EU. Rheumatoid arthritis (RA) and inflammatory bowel diseases (IBD) are two archetypal CIDs with a particularly high unmet medical need and impact on European health care systems. Objectives: The PerPrev-CID consortium aims to set up new standards for decision support tool development for preventive and early therapeutic interventions in RA and IBD.
Selected main aims are: (i) To define actionable predictors from longitudinal multi-level Omics and clinical data integration In RA and IBD. We will identify markers indicating progression from pre-symptomatic to manifest disease and signatures predicting early disease relapse (ii) To develop new tools for home-based and continuous assessment of patient-related data dimensions using digital health apps/wearables, including more innovative, objective parameters, such as movement patterns, physical activity, and sleep. (iii) To assess the health-promoting effects of interfering with the tryptophan pathway in a proof-of-concept nutritional study in early RA and IBD. (iv) To study ethical, legal and economic consequences of risk assessment and early low-threshold preventive interventions.
Important aspects are the communication of the risk concept, economic implications of broad testing and interventions as well as patients´ perception of the concept of risk prediction. Expected impact: We will develop prototype solutions for privacy-preserving AI-based data analysis for research and clinical application and will test a first proof-of-concept low threshold intervention in RA and IBD. Our approaches will provide a clear health benefit to the citizens of the EU by improving health outcomes, empowering joint decision making and contributing to appropriate action plans to reduce the avoidable burden of the diseases.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitatsklinikum Schleswig-Holstein | Lübeck | Germany | Coordinator |
| International Federation of Crohn's and Ulcerative Colitis Associations | Bruxelles / Brussel | Belgium | Participant |
| Universite De Liege | Liege | Belgium | Participant |
| Vib Vzw | Zwijnaarde - Gent | Belgium | Participant |
| European Alliance of Associations for Rheumatology | Zurich | Switzerland | Associatedpartner |
| Universite De Geneve | Geneve | Switzerland | Associatedpartner |
| Christian-Albrechts-Universitaet Zu Kiel | Kiel | Germany | Third party |
| Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV | Bonn | Germany | Participant |
| Eurice European Research and Project Office GmbH | St Ingbert | Germany | Participant |
| Weizmann Institute of Science | Rehovot | Israel | Participant |
| Universita Cattolica Del Sacro Cuore | Milano | Italy | Participant |
| Lietuvos Sveikatos Mokslu Universitetas | Kaunas | Lithuania | Participant |
| Lietuvos Sveikatos Mokslu Universiteto Ligonine Kauno Klinikos | Kaunas | Lithuania | Third party |
| Stichting Radboud Universiteit | Nijmegen | Netherlands | Participant |
| The University of Manchester | Manchester | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI